1. Home
  2. OGEN vs PPBT Comparison

OGEN vs PPBT Comparison

Compare OGEN & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oragenics Inc.

OGEN

Oragenics Inc.

HOLD

Current Price

$0.16

Market Cap

2.2M

Sector

Health Care

ML Signal

HOLD

Logo Purple Biotech Ltd.

PPBT

Purple Biotech Ltd.

SELL

Current Price

$1.53

Market Cap

2.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
OGEN
PPBT
Founded
1996
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2M
2.4M
IPO Year
2010
2014

Fundamental Metrics

Financial Performance
Metric
OGEN
PPBT
Price
$0.16
$1.53
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 246.6K
27.0K
Earning Date
11-12-2026
11-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.13
$0.41
52 Week High
$1.11
$5.18

Technical Indicators

Market Signals
Indicator
OGEN
PPBT
Relative Strength Index (RSI) 14.14 56.46
Support Level N/A $1.34
Resistance Level $0.59 $1.60
Average True Range (ATR) 0.03 0.17
MACD -0.02 0.04
Stochastic Oscillator 10.60 62.63

Price Performance

Historical Comparison
OGEN
PPBT

About OGEN Oragenics Inc.

Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.

Share on Social Networks: